Cannell & Spears’s Regeneron Pharmaceuticals REGN Stock Holding History

Cannell & Spears’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.2M	Sell	68,914 -20,481	-23%	-$15.7M	1.04%	27
2025 Q4	$69M	Buy	89,395 +59,316	+197%	+$40.3M	1.29%	22
2025 Q3	$16.9M	Buy	30,079 +3,618	+14%	+$2.05M	0.32%	86
2025 Q2	$13.9M	Sell	26,461 -38,065	-59%	-$21.2M	0.28%	86
2025 Q1	$40.9M	Buy	64,526 +48,471	+302%	+$33.3M	0.88%	34
2024 Q4	$11.4M	Buy	16,055 +5,415	+51%	+$4.54M	0.23%	91
2024 Q3	$11.2M	Buy	10,640 +78	+0.7%	+$86.8K	0.22%	96
2024 Q2	$11.1M	Sell	10,562 -277	-3%	-$269K	0.23%	90
2024 Q1	$10.4M	Buy	+10,839	New	+$10.3M	0.22%	98

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cannell & Spears's REGN Position: Q1 2026 in Review

Cannell & Spears reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q1 2026, selling an estimated $15.7M and leaving 68,914 shares worth $53.2M. The position accounts for 1.04% of the portfolio, ranked #27.

Cannell & Spears first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $69M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Cannell & Spears held 68,914 shares of Regeneron Pharmaceuticals worth $53.2M as of Q1 2026.
Cannell & Spears sold 20,481 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15.7M.
Regeneron Pharmaceuticals made up 1.04% of Cannell & Spears's portfolio in Q1 2026, its #27 holding.
Cannell & Spears first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Cannell & Spears's Regeneron Pharmaceuticals position peaked at $69M in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.